LETTER TO THE EDITOR

Comment on: “Investigation of intermediate CAG alleles of the HTT in the general population of Rio de Janeiro, Brazil, in comparison with a sample of Huntington disease-affected families.”

We read with great interest the manuscript by Apolinário and colleagues (Apolinário, da Silva, Agostinho & Paiva, 2020) about the Investigation of intermediate CAG alleles of the HTT in the general population of Rio de Janeiro, and although we understand that was not the aim of the article, we would like to contribute with an interesting clinical finding, of an ongoing study of a southern Brazilian cohort, that may highlight the discussion about the importance of intermediate alleles in Huntington's disease (HD).

In a group of symptomatic patients with HD (OMIM: 143100) in a tertiary hospital in Brazil, two patients among a total of 41 patients evaluated were observed to present a classic HD phenotype. But interestingly, both of them had genetic CAG expansion at the intermediate alleles (IA) range—a mother and her son, with 29 and 34 CAG repetitions, respectively. Both patients had chorea, dystonia, and classical features of HD, indistinguishable from other patients in the classical CAG expansion.

In conformity with those findings, there is a growing scientific support of IA patients presenting a classical HD phenotype (Andrich et al., 2008; Cubo et al., 2016; Savitt & Jankovic, 2012). The probability of IA to manifest HD is of extremely relevance, not only for the pathogenesis comprehension of disease, but also for clinical and genetic counseling, since those individuals are often reassured as having no chance of developing HD (Squitieri & Jankovic, 2012).

Due to the expansion of CAG repeats greater than 26 CAG repeats, the HTT (4p16.3) gains an extra polyglutamine tail at the N-terminal region, and once expanded HTT can be cleaved into fragments by proteases such as calpains and caspas. These protein fragments accumulate in specific regions as the medium spiny neurons inside nerve cells causing neuronal toxicity (Reilmann, Leavitt, & Ross, 2014).

The explanation of why some individuals with IA exhibit clinical symptoms while others do not is still controversial. A plausible justification is the presence of somatic mosaicism, and individuals with IA that manifest a HD phenotype, express longer CAG repeats in their medium-striatal neurons than in other tissues in the same individual (Leija-Salazar, Piette, & Proukakis, 2018). Mosaicism for CAG repeat length has been reported in CNS (Telenius et al., 1994). Therefore, age of onset and progression may depend also on other biological or environmental factors (Squitieri, Sabbadini, & Mandich, 2018; Wexler, Lorimer, & Porter, 2004), and there are studies of candidate gene modifiers that may influence age at onset and progression of the disease (Li, Friedman, & Li, 2007).

It is essential that the classification corresponds to the clinical reality, so that genetic counseling and, even more, medical care can be done correctly. Since not considering the actual range of CAG repetitions in which HD may manifest, we may deprive the patient of adequate follow-up, and even making the treatment more distant, once new treatments are emerging.

It is likely that patients who express 27–35 CAG repeats have an even lower penetrance than those with 36–39, but the possibility of IA individuals producing a classic HD phenotype seems undeniable.

In this way, we may suggest that the IA range might belong to the same group of reduced penetrance range of HD, and we understand that a brand new genotypic and phenotypic classification of HD is imminent.

ACKNOWLEDGMENTS

Not applied.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS
GLF, ATM, and HAGT contributed to the initial development of the research, drafting, and review of the final manuscript. GLF takes responsibility for its overall content. All authors have read and approved the final manuscript.

FUNDING INFORMATION
No funding to declare.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The study was approved at the ethics committee by number: CAAE 67,130,217.1.1001.0096. Written informed consent for participating in this study was obtained from all patients.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study are included in this published article.

REFERENCES
Andrich, J., Arning, L., Wieczorek, S., Kraus, P. H., Gold, R., & Saft, C. (2008). Huntington’s disease as caused by 34 CAG repeats. Movement Disorders, 23(6), 879–881. https://doi.org/10.1002/mds.21958
Apolinário, T. A., da Silva, I. D. S., Agostinho, L. D. A., & Paiva, C. L. A. (2020). Investigation of intermediate CAG alleles of the HTT in the general population of Rio de Janeiro, Brazil, in comparison with a sample of Huntington disease-affected families. Molecular Genetics & Genomic Medicine, e1181. https://doi.org/10.1002/mgg3.1181
Cubo, E., Ramos-Arroyo, M. A., Martínez-Horta, S., Martínez-Descalls, A., Calvo, S., Gil-Polo, C. et al (2016). Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 87, 571–578. https://doi.org/10.1212/WNL.0000000000002944
Leija-Salazar, M., Piette, C., & Proukakis, C. (2018). Review: Somatic mutations in neurodegeneration. Neuropathology and Applied Neurobiology, 44, 267–285. https://doi.org/10.1111/nan.12465
Li, X. J., Friedman, M., & Li, S. (2007). Interacting proteins as genetic modifiers of Huntington disease. Trends in Genetics, 23, 531–533. https://doi.org/10.1016/j.tig.2007.07.007
Quarrell, O. W. J., Rigby, A. S., Barron, L., Crow, Y., Dalton, A., Dennis, N., … Warner, J. (2007). Reduced penetrance alleles for Huntington’s disease: A multi-centre direct observational study. Journal of Medical Genetics, 44, e68. https://doi.org/10.1136/jmg.2006.045120
Reilmann, R., Leavitt, B. R., & Ross, C. A. (2014). Diagnostic criteria for Huntington’s disease based on natural history. Movement Disorders, 29, 1335–1341. https://doi.org/10.1002/mds.26011
Savitt, D., & Jankovic, J. (2019). Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. Journal of the Neurological Sciences, 402, 57–61. https://doi.org/10.1016/j.jns.2019.05.010
Squitieri, F., & Jankovic, J. (2012). Huntington’s disease: How intermediate are intermediate repeat lengths? Movement Disorders, 27, 1714–1717. https://doi.org/10.1002/mds.25172
Squitieri, F., Sabbadini, G., Mandich, P. et al (2018). Family and molecular data for a fine analysis of age at onset in Huntington disease. American Journal of Medical Genetics. Part A, 95, 366–373. https://doi.org/10.1002/ajmg.13>3.0.co;2-2
Telenius, H., Kremer, B., Goldberg, Y. P., Theilmann, J., Andrew, S. E., Zeisler, J., … Hayden, M. R. (1994). Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nature Genetics, 6, 409–414. https://doi.org/10.1038/ng0494-409. https://doi.org/10.1038/ng0494-409
Wexler, N. S., Lorimer, J., & Porter, J. (2004). Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proceedings of the National Academy of Sciences of the United States of America, 101, 3498–3503. https://doi.org/10.1073/pnas.0308679101